June 7, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine
Combination and IV Rigosertib at 2016 ASCO Annual Meeting
TOKYO, Japan, June 7, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,“SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc.
(Headquarters: Newtown, PA, “Onconova”) announced on June 6, 2016 (EST) thepresentation of data in two poster presentations for (i) the mechanistic rationale for
combining oral rigosertib with azacitidine and (ii) the background and rationale for theIV rigosertib trial, at the 2016 American Society of Clinical Oncology (“ASCO”) Annual
Meeting being held from June 3-7, 2016 in Chicago, Illinois.
For the oral rigosertib/azacitidine poster presentation, investigators evaluated andconfirmed the synergistic activity of the oral rigosertib/azacitidine combination in
myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) cell lines
and patients’ bone marrow, studies in which a novel effect on epigenetics was alsorevealed.

Onconova is currently evaluating the oral rigosertib and azacitidine

combination in a fully enrolled, multi-center Phase 2 trial (NCT01926587). Onconova
plans to share these results with regulatory agencies, and an update on this study will
be presented at the European Hematology Association meeting to be held later thismonth.
In the second poster presentation, the novel design and eligibility criteria employed in
Onconova’s global randomized Phase 3 INSPIRE trial for IV rigosertib in the 2nd-line
MDS patient setting were outlined by the study’s investigators. The study is currently
enrolling patients in the U.S., Europe and Japan at more than 50 sites.
SymBio obtained the licensing rights for rigosertib in July, 2011 and retains thedevelopment rights for Japan and Korea.
For more details in this press release, please visit Onconova’s homepage at
http://investor.onconova.com/releases.cfm

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Myelodysplastic Syndromes (MDS)MDS patients often require frequent blood transfusions due to the development ofsevere anemia (decrease in the number of red blood cells), with a high rate ofprogression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS
patients in Japan alone, with the number of cases expected to increase as thepopulation ages. MDS and AML are widely recognized as two blood disorders that aredifficult to manage given the limited therapeutic options available for patients,
particularly for patients who have a drug-resistant form of the disease. A high unmet
medical need clearly exists for the establishment of new effective therapies to treat both
lower-risk MDS and higher-risk MDS.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical andpre-clinical stage drug development candidates are derived from its extensive chemical
library and are designed to work against specific cellular pathways that are importantin cancer cells, while causing minimal damage to normal cells. In addition to rigosertib,
Onconova's most advanced drug candidate under development, two other drugcandidates are in clinical trials and several other compounds in the pre-clinical stage ofdevelopment. For more information, please visit http://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida
who previously served concurrently as Corporate VP of Amgen Inc. and founding
President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned
subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters:
Menlo Park, California, USA, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as
it aspires to be a leading global specialty biopharmaceutical company dedicated toaddressing underserved medical needs with main therapeutic focus in oncology,
hematology and pain management.